- Helge Gad
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Tobias Koolmeister
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Ann-Sofie Jemth
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Saeed Eshtad
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Sylvain A. Jacques
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Cecilia E. Ström
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Linda M. Svensson
(Stockholm University, S-106 91 Stockholm, Sweden)
- Niklas Schultz
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Thomas Lundbäck
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Berglind Osk Einarsdottir
(Sahlgrenska Translational Melanoma Group, Sahlgrenska Cancer Center, University of Gothenburg and Sahlgrenska University Hospital, S-405 30 Gothenburg, Sweden)
- Aljona Saleh
(Stockholm University, S-106 91 Stockholm, Sweden)
- Camilla Göktürk
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Pawel Baranczewski
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Uppsala University Drug Optimization and Pharmaceutical Profiling Platform, Uppsala University, S-751 23 Uppsala, Sweden)
- Richard Svensson
(Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Uppsala University Drug Optimization and Pharmaceutical Profiling Platform, Uppsala University, S-751 23 Uppsala, Sweden)
- Ronnie P.-A. Berntsson
(Stockholm University, S-106 91 Stockholm, Sweden)
- Robert Gustafsson
(Stockholm University, S-106 91 Stockholm, Sweden)
- Kia Strömberg
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Kumar Sanjiv
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Marie-Caroline Jacques-Cordonnier
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Matthieu Desroses
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Anna-Lena Gustavsson
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Roger Olofsson
(Sahlgrenska Translational Melanoma Group, Sahlgrenska Cancer Center, University of Gothenburg and Sahlgrenska University Hospital, S-405 30 Gothenburg, Sweden)
- Fredrik Johansson
(Microbiology and Toxicology, Stockholm University, S-106 91 Stockholm, Sweden)
- Evert J. Homan
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Olga Loseva
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Lars Bräutigam
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Lars Johansson
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Andreas Höglund
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Anna Hagenkort
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Therese Pham
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Mikael Altun
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Fabienne Z. Gaugaz
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Uppsala University Drug Optimization and Pharmaceutical Profiling Platform, Uppsala University, S-751 23 Uppsala, Sweden)
- Svante Vikingsson
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Clinical Pharmacology, Linköping University, S-58185 Linköping, Sweden)
- Bastiaan Evers
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Present addresses: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1006 Amsterdam, The Netherlands (B.E.); Department of Immunology, Genetics, and Pathology, Uppsala University, S-751 23 Uppsala, Sweden (T.D.).)
- Martin Henriksson
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Karl S. A. Vallin
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Olov A. Wallner
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Lars G. J. Hammarström
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Elisee Wiita
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Ingrid Almlöf
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Christina Kalderén
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Hanna Axelsson
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Tatjana Djureinovic
(Microbiology and Toxicology, Stockholm University, S-106 91 Stockholm, Sweden
Present addresses: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1006 Amsterdam, The Netherlands (B.E.); Department of Immunology, Genetics, and Pathology, Uppsala University, S-751 23 Uppsala, Sweden (T.D.).)
- Jordi Carreras Puigvert
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Maria Häggblad
(Science for Life Laboratory, RNAi Cell Screening Facility, Stockholm University, S-106 91 Stockholm, Sweden)
- Fredrik Jeppsson
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Ulf Martens
(Science for Life Laboratory, RNAi Cell Screening Facility, Stockholm University, S-106 91 Stockholm, Sweden)
- Cecilia Lundin
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Bo Lundgren
(Science for Life Laboratory, RNAi Cell Screening Facility, Stockholm University, S-106 91 Stockholm, Sweden)
- Ingrid Granelli
(Stockholm University, S-106 91 Stockholm, Sweden)
- Annika Jenmalm Jensen
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Per Artursson
(Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden
Uppsala University Drug Optimization and Pharmaceutical Profiling Platform, Uppsala University, S-751 23 Uppsala, Sweden)
- Jonas A. Nilsson
(Sahlgrenska Translational Melanoma Group, Sahlgrenska Cancer Center, University of Gothenburg and Sahlgrenska University Hospital, S-405 30 Gothenburg, Sweden)
- Pål Stenmark
(Stockholm University, S-106 91 Stockholm, Sweden)
- Martin Scobie
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Ulrika Warpman Berglund
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)
- Thomas Helleday
(Science for Life Laboratory, Karolinska Institutet, S-171 21 Stockholm, Sweden)